IMBiologics

IMBiologics specializes in the research and development of innovative immunomodulatory antibody therapeutics aimed at treating autoimmune diseases and cancer. The company operates in the biopharmaceutical sector, focusing on creating novel drugs that help restore homeostasis, the body's natural balance. IMBiologics serves a global clientele, including healthcare providers and patients in need of advanced treatments for complex diseases. The business model revolves around leveraging proprietary platform technology and in-licensed drug candidates to accelerate drug development. Revenue is generated through licensing deals, partnerships, and the commercialization of its therapeutic products. The company has successfully raised significant funding, including a 4B KRW seed round and a 13B KRW Series A financing round, to support its R&D activities and growth initiatives.

Keywords: immunomodulatory, antibody therapeutics, autoimmune diseases, cancer, biopharmaceutical, homeostasis, platform technology, licensing deals, R&D, innovative drugs.